Holen Sie sich die Stockscreener-App
38.38
0.24%
0.1513
Schlusskurs vom Vortag:
$38.23
Offen:
$37.82
24-Stunden-Volumen:
186.66K
Relative Volume:
0.07
Marktkapitalisierung:
$5.15B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-237.54M
KGV:
-15.33
EPS:
-2.5033
Netto-Cashflow:
$-145.05M
1W Leistung:
-1.49%
1M Leistung:
-16.95%
6M Leistung:
+108.83%
1J Leistung:
+0.00%
1-Tages-Spanne:
$37.68
$38.93
1-Wochen-Bereich:
$37.32
$39.26
52-Wochen-Spanne:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Firmenname
Definium Therapeutics Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
38.33 | 5.14B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
522.23 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.44 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Stifel | Buy |
| 2026-04-10 | Eingeleitet | Piper Sandler | Overweight |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-08-04 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-01-28 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics Stock (DFTX) Opinions on Analyst Upgrade and Regulatory Progress - Moomoo
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics (DFTX) CEO gets 40K-share award, sells stock for taxes - Stock Titan
Definium Therapeutics, Inc. (NASDAQ: DFTX) Stock Price, News & Analysis - Kalkine
Transcript : Definium Therapeutics, Inc.Special Call - marketscreener.com
After $1.23M sale, Definium Therapeutics (DFTX) holder plans another stock trade - Stock Titan
Stifel reiterates Buy on Definium Therapeutics stock, $60 target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on Definium Therapeutics stock, $60 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Definium Therapeutics Announces New Employee Inducement Grants - The Chronicle-Journal
Wells Fargo Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $72 - moomoo.com
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Stifel confident in Definium Therapeutics stock after management dinner By Investing.com - Investing.com Nigeria
Stifel confident in Definium Therapeutics stock after management dinner - Investing.com
SW Weekly: Why I Can't Buy Definium Following Phase 3 LSD Readout. (NASDAQ:DFTX) - Seeking Alpha
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Business Wire
Certain Common Shares of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
Certain Warrants of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
DRIEHAUS CAPITAL MANAGEMENT LLC Expands Definium Therapeutics In - GuruFocus
Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX) - MarketBeat
Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results - Sahm
Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120 - TipRanks
Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America - MarketBeat
Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT - Sahm
DFTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential - Investing.com Nigeria
Definium Therapeutics (DFTX) Reports Positive Phase 3 GAD Trial Results Amid High Valuation - GuruFocus
DFTX Maintained by Maxim Group -- Price Target Raised to $55 - GuruFocus
Definium Therapeutics Price Target Raised to $55.00/Share From $50.00 by Maxim Group - Moomoo
Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake - Stock Titan
Definium Therapeutics' Voyage Trial Success Reshapes Valuation Debate for Anxiety Drug - finance.biggo.com
DFTX News Today | Why did Definium Therapeutics stock go down today? - MarketBeat
Finanzdaten der Definium Therapeutics Inc-Aktie (DFTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):